C Diff Infection News Today

Novel therapeutics could offer clinicians an additional tool in developing their patient treatment plans, particularly for those with no response or resistance to existing therapies.

Growth hormone deficiency appears to be linked to a particular microbiome signature that could help with the early diagnosis and treatment of short stature, suggest study.

Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.

The American Academy of Pediatrics endorsed fecal transplants to eliminate a particular infection in children and called for more research about other uses.

Researchers found significant improvements for intestinal microbiota transplant in one type of inflammatory bowel disease but not another.

Pediatric patients receiving a donor stem cell transplant who have healthier pretransplant gut microbiota diversity show improved rates of survival and a lower risk of acute GvHD.

Fecal microbiota transplant (FMT) promotes restoration of the gut microbiota, enzymes, and immune responses, and reduces ammonia build-up in patients with cirrhosis, a pilot study found.

Already successful in treating C difficile, fecal microbiota transplant could be applied to noncommunicable diseases, but better understanding of donor-recipient pairing is critical.

Clinicians now have two approved options for recurrent infections after antibiotic treatment.

The FDA on Wednesday approved Seres Therapeuticss pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants.